The proposed sale is small and by a director, not the CEO/CFO, so it carries limited signal. Monitor for any larger insider sales or changes in insider filing patterns, but this filing alone does not warrant concern.
LGND drugs
LGND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $313.52entry
- T+1 · 13d ago +0.83%α −0.82% · $316.13
- T+5 · 7d ago +0.20%α +0.79% · $314.16
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jason Aryeh, a director of Ligand Pharmaceuticals, filed a Form 144 notice of intent to sell 700 shares of Class B common stock, with an approximate market value of $221,595. The shares were acquired between May and July 2019 via secondary market purchases. The sale is small relative to the company's $6.3B market cap and the insider's likely total holdings, making it a routine diversification move.
Key Facts
- Jason Aryeh, a director, filed Form 144 to sell 700 shares of Class B common stock.
- Estimated proceeds of $221,595 based on filing date price.
- Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases.
- The sale represents a tiny fraction of the company's $6.3B market cap.
- The filing is an advance notice of intent to sell, not a completed transaction.
Financial Impact
Sale of 700 shares valued at approximately $221,595, negligible relative to $6.3B market cap.
Risk Factors
- Form 144 is only an intent to sell; the sale may not occur.
- No context on the insider's total holdings, so proportionality is estimated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001957799-26-000192 |
| Document: 0001957799-26-000192-index.html | 0001957799-26-000192 |
| Document: 0001957799-26-000192.txt | 0001957799-26-000192 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers